In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
from Top Health News -- ScienceDaily https://ift.tt/2Q7y3t5
the news of the day, for today, top news of today, world news today live, top local news, top news stories of the day, top news today in the world, news today nyc, top news today local,
Subscribe to:
Post Comments (Atom)
San Diego physician, medical practice ordered to pay $3.8M for alleged false claims
from Yahoo News - Latest News & Headlines https://ift.tt/mXRgIjn
-
from Yahoo News - Latest News & Headlines https://ift.tt/m2VMCS1
-
from Yahoo News - Latest News & Headlines https://ift.tt/jYPuwNf
-
from Yahoo News - Latest News & Headlines https://ift.tt/Ot2Ebrh
No comments:
Post a Comment